Colleen Kusy
Stock Analyst at Baird
(3.65)
# 3,380
Out of 5,182 analysts
53
Total ratings
42.55%
Success rate
11.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Outperform | $65 → $90 | $71.90 | +25.17% | 3 | Apr 14, 2026 | |
| CLYM Climb Bio | Maintains: Outperform | $9 → $12 | $9.50 | +26.32% | 2 | Mar 6, 2026 | |
| ARGX argenx SE | Maintains: Neutral | $858 → $867 | $783.74 | +10.62% | 2 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $104.04 | +51.86% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $36.61 | -7.12% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $40.95 | +26.98% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $9.52 | +152.10% | 5 | Oct 3, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $44.90 | +15.81% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.09 | +46.70% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $27.11 | +51.24% | 4 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $6 | $1.84 | +226.09% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $10.19 | +145.34% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $8.66 | +2,324.94% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $3.43 | +891.25% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.48 | +6,518.71% | 1 | Nov 2, 2021 |
Spyre Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $65 → $90
Current: $71.90
Upside: +25.17%
Climb Bio
Mar 6, 2026
Maintains: Outperform
Price Target: $9 → $12
Current: $9.50
Upside: +26.32%
argenx SE
Feb 27, 2026
Maintains: Neutral
Price Target: $858 → $867
Current: $783.74
Upside: +10.62%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $104.04
Upside: +51.86%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $36.61
Upside: -7.12%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $40.95
Upside: +26.98%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $9.52
Upside: +152.10%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $44.90
Upside: +15.81%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.09
Upside: +46.70%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $27.11
Upside: +51.24%
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.84
Upside: +226.09%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $10.19
Upside: +145.34%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $8.66
Upside: +2,324.94%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $3.43
Upside: +891.25%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.48
Upside: +6,518.71%